Huge Samsung BioLogics IPO Reflects Rosy Manufacturing Outlook
Executive Summary
Samsung BioLogics has successful floated in one of South Korea’s largest ever IPOs and appears to be on track to becoming the top global contract manufacturer of biologics amid rising demand from cost-conscious global clients.
You may also be interested in...
Samsung BioLogics Under Spotlight Over Accounting Handling Of Biogen JV
Samsung BioLogics shares plunge on suspicions it has violated accounting related to affiliate Samsung Bioepis, but the company says its accounting meets IFRS standards and denies any transgressions. Samsung BioLogics could face a penalty, depending on the outcome of upcoming financial authority meetings and whether Biogen exercises its call option on Samsung Bioepis in the coming months.
Samsung BioLogics Under Spotlight Over Accounting Handling Of Biogen JV
Samsung BioLogics shares plunge on suspicions it has violated accounting related to affiliate Samsung Bioepis, but the company says its accounting meets IFRS standards and denies any transgressions. Samsung BioLogics could face a penalty, depending on the outcome of upcoming financial authority meetings and whether Biogen exercises its call option on Samsung Bioepis in the coming months.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.